zurück

Ceftolozane / tazobactam (new indication: bacterial infections; patients aged < 18 years (antibiotic of last resort))

 

Subject:

  • Active Sustance: Ceftolozance / tazobactam
  • Name: Zerbaxa®
  • Therapeutic area: Bacterial infections
  • Pharmaceutical company: MSD Sharp & Dohme GmbH

 

Time table:

  • Start: 15.08.2022
  • Publication of assessment: 15.11.2022
  • End of public hearing: 06.12.2022
  • Final decision by G-BA: beginning of February 2023

 

Comparative therapy:

  • No comparative therapy due status as antibiotic of last resort